See more : DIP Corporation (2379.T) Income Statement Analysis – Financial Results
Complete financial analysis of Soligenix, Inc. (SNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soligenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fagron NV (ARSUF) Income Statement Analysis – Financial Results
- Shenzhen Institute of Building Research Co., Ltd. (300675.SZ) Income Statement Analysis – Financial Results
- SBI Life Insurance Company Limited (SBILIFE.NS) Income Statement Analysis – Financial Results
- AB Volvo (publ) (VLVLY) Income Statement Analysis – Financial Results
- Genie Energy Ltd. (GNE-PA) Income Statement Analysis – Financial Results
Soligenix, Inc. (SNGX)
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | 5.24M | 5.43M | 10.45M | 8.77M | 7.04M | 3.22M | 3.14M | 7.66M | 1.95M | 2.82M | 2.31M | 1.26M | 2.31M | 3.08M | 997.48K | 83.82K | 0.00 | 0.00 | 0.00 | 1.00 | 200.00K | 100.00K | 0.00 |
| Cost of Revenue | 742.05K | 550.82K | 728.64K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M | 6.88M | 5.31M | 2.54M | 2.59M | 2.11M | 1.64M | 1.48M | 1.89M | 943.39K | 1.97M | 2.07M | 936.64K | 76.20K | 0.00 | 0.00 | 0.00 | -1.41M | -1.70M | -500.00K | 0.00 |
| Gross Profit | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | 643.73K | 1.12M | 2.02M | 1.89M | 1.73M | 679.87K | 551.55K | 5.55M | 309.23K | 1.33M | 423.83K | 314.63K | 347.95K | 1.01M | 60.85K | 7.62K | 0.00 | 0.00 | 0.00 | 1.41M | 1.90M | 600.00K | 0.00 |
| Gross Profit Ratio | 11.59% | 41.95% | 11.60% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | 15.88% | 47.31% | 18.35% | 25.01% | 15.04% | 32.80% | 6.10% | 9.09% | 0.00% | 0.00% | 0.00% | 140,775,100.00% | 950.00% | 600.00% | 0.00% |
| Research & Development | 3.31M | 7.94M | 8.39M | 15.15M | 8.12M | 6.75M | 5.51M | 4.30M | 5.40M | 5.09M | 5.07M | 2.61M | 6.27M | 5.68M | 4.52M | 1.73M | 3.10M | 4.62M | 3.68M | 3.66M | 2.73M | 2.94M | 2.47M | 956.74K | 2.03M | 3.10M | 1.80M | 906.46K |
| General & Administrative | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.56M | 0.00 | 2.50M | 2.86M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 2.51M | 1.97M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 2.50M | 2.86M | 2.15M | 3.54M | 3.11M | 2.16M | 2.32M | 2.51M | 2.99M | 1.97M | 2.10M | 3.05M | 3.50M | 1.50M | 317.24K |
| Other Expenses | 0.00 | -132.87K | -174.77K | -95.36K | -433.59K | 0.00 | 0.00 | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 0.00 | 0.00 | 0.00 | 3.54M | 3.93M | 2.16M | 2.32M | 2.51M | 2.99M | 12.15M | 2.10M | 4.45M | 5.20M | 2.00M | 0.00 |
| Operating Expenses | 7.80M | 14.50M | 13.06M | 19.03M | 11.17M | 9.70M | 8.72M | 7.72M | 9.00M | 8.49M | 7.84M | 5.24M | 8.51M | 8.19M | 7.38M | 3.88M | 6.64M | 8.55M | 5.84M | 5.98M | 5.23M | 5.93M | 14.63M | 3.06M | 6.48M | 8.30M | 3.80M | 1.26M |
| Cost & Expenses | 8.54M | 15.05M | 13.79M | 20.85M | 14.74M | 14.30M | 13.03M | 16.16M | 15.88M | 13.80M | 10.38M | 7.84M | 10.62M | 9.83M | 8.87M | 5.77M | 7.59M | 10.51M | 7.91M | 6.91M | 5.31M | 5.93M | 14.63M | 3.06M | 5.08M | 6.60M | 3.30M | 1.26M |
| Interest Income | 0.00 | 822.61K | 904.50K | 10.88K | 148.97K | 159.01K | 29.91K | 0.00 | 0.00 | 1.31K | 1.96K | 6.20K | 7.44K | 12.07K | 21.92K | 37.07K | 164.85K | 41.51K | 114.79K | 66.54K | 28.71K | 105.68K | 424.03K | 747.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.13K | 822.61K | 862.58K | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 742.00 | 2.68K | 3.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -35.84K | -35.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55K | 137.28K | 150.45K | 193.04K | 177.56K | 44.06K | 68.56K | 89.93K | 247.46K | 245.79K | 230.07K | 230.63K | 226.03K | 185.70K | 175.60K | 149.18K | 119.57K | 137.04K | 194.28K | 302.45K | 226.14K | 345.50K | 188.53K | 156.86K | 1.41M | 1.70M | 500.00K | 204.46K |
| EBITDA | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | -9.01M | -7.53M | -5.62M | -6.86M | -6.52M | -6.93M | -4.45M | -2.73M | -7.45M | -5.86M | -3.31M | -6.21M | -8.02M | -4.64M | -5.61M | -5.00M | -6.45M | -3.86M | -2.90M | -3.67M | -4.80M | -2.70M | -1.06M |
| EBITDA Ratio | -935.58% | -1,483.34% | -1,565.17% | -781.06% | -216.96% | -171.99% | -138.52% | -72.27% | -64.56% | -84.51% | -101.47% | -141.83% | -35.58% | -394.36% | -208.57% | -143.13% | -493.33% | -313.28% | -150.88% | -562.94% | -5,934.78% | 0.00% | 0.00% | 0.00% | -80,576,000.00% | 5,250.00% | -2,900.00% | 0.00% |
| Operating Income | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | -9.06M | -7.59M | -5.71M | -7.11M | -10.76M | -7.16M | -4.69M | -2.96M | -7.88M | -6.05M | -3.46M | -6.33M | -8.20M | -4.84M | -5.92M | -5.23M | -5.93M | -14.63M | -3.06M | -5.08M | -6.40M | -3.20M | -1.26M |
| Operating Income Ratio | -917.12% | -1,486.55% | -1,573.05% | -783.71% | -218.31% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | -404.51% | -214.89% | -149.59% | -502.94% | -354.50% | -157.20% | -593.21% | -6,236.06% | 0.00% | 0.00% | 0.00% | -507,562,800.00% | -3,200.00% | -3,200.00% | 0.00% |
| Total Other Income/Expenses | -210.59K | -714.37K | -449.60K | 61.09K | 574.75K | 159.01K | 29.91K | 1.93M | -1.21M | 3.44M | -3.65M | 6.20K | 7.44K | 246.03K | 16.84K | 33.80K | 162.44K | 36.20K | 114.79K | 45.54K | -61.65K | -5.92K | -5.92K | -2.43M | -2.86M | -15.20M | 200.00K | 74.85K |
| Income Before Tax | -7.91M | -14.95M | -13.42M | -18.53M | -9.97M | -8.90M | -7.56M | -3.78M | -8.32M | -7.32M | -10.81M | -4.68M | -2.95M | -7.63M | -6.05M | 0.00 | -6.33M | -9.02M | 0.00 | -5.92M | -5.29M | -14.63M | -14.63M | -5.49M | -7.94M | -21.60M | -3.00M | -1.19M |
| Income Before Tax Ratio | -942.21% | -1,575.84% | -1,627.59% | -785.16% | -215.26% | -169.80% | -139.23% | -36.13% | -94.89% | -103.99% | -335.26% | -148.97% | -38.53% | -391.88% | -214.97% | 0.00% | -503.05% | -389.79% | 0.00% | -593.15% | -6,309.62% | 0.00% | 0.00% | 0.00% | -793,774,600.00% | -10,800.00% | -3,000.00% | 0.00% |
| Income Tax Expense | -1.77M | -1.15M | -864.74K | -836.89K | -610.68K | 159.01K | -416.81K | -530.14K | -488.93K | -616.87K | -750.36K | -521.46K | -574.16K | -245.81K | -16.84K | -33.80K | -162.44K | -36.20K | -114.79K | -45.54K | 61.65K | -965.43K | 5.92K | 1.74M | 2.43M | 15.40M | 0.00 | 0.00 |
| Net Income | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M | -8.90M | -7.15M | -3.25M | -7.83M | -6.71M | -10.06M | -4.16M | -2.38M | -7.39M | -6.03M | -3.42M | -6.16M | -8.16M | -4.72M | -5.87M | -5.29M | -4.97M | -14.63M | -4.80M | -7.50M | -21.80M | -3.20M | -1.19M |
| Net Income Ratio | -731.60% | -1,454.12% | -1,522.68% | -749.69% | -202.07% | -169.80% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | -379.26% | -214.29% | -148.12% | -490.03% | -352.93% | -153.47% | -588.64% | -6,309.62% | 0.00% | 0.00% | 0.00% | -750,101,900.00% | -10,900.00% | -3,200.00% | 0.00% |
| EPS | -12.66 | -76.96 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -223.73 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| EPS Diluted | -12.66 | -76.89 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -320.56 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| Weighted Avg Shares Out | 484.88K | 179.29K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 10.12K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
| Weighted Avg Shares Out (Dil) | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 14.93K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
Why Is Soligenix (SNGX) Stock Up 58% Today?
Soligenix (NASDAQ: SNGX ) stock is rocketing higher on Monday after getting an orphan drug designation for the active ingredient in MarVax. This comes from the Food and Drug Administration's (FDA) Office of Orphan Products Development.
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study PRINCETON, N.J. , April 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical...
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PRINCETON, N.J. , March 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent...
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
Phase 2a clinical study of SGX945 in Behçet's Disease initiating in 2024 PRINCETON, N.J. , Feb. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 26, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Mobilicom Limited (NASDAQ:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 27,...
Soligenix to Present at The Microcap Conference
PRINCETON, N.J. , Jan. 25, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the...
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PRINCETON, N.J. , Jan. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its...
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Clinical Success Achieved in Second Cohort of Patients PRINCETON, N.J. , Jan. 4, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there...
Source: https://incomestatements.info
Category: Stock Reports